CDT Equity Completes 1-for-25 Reverse Split to Regain Nasdaq Compliance
CDT is trading near its 52-week low of $1.22 (0.0% above the low) on elevated volume (1.9× avg).
Summary
CDT Equity completed a 1-for-25 reverse stock split to maintain Nasdaq listing, reducing shares to ~1.12M while leaving 250M authorized shares available for future dilution.
Key Events · Corporate Governance and Compliance · CDT
-
1-for-25 Reverse Split Completed
Effective September 28, 2026, every 25 shares were combined into one, reducing outstanding shares to approximately 1,124,515. The ratio was steeper than the 1-for-10 split announced in July 2026.
-
Authorized Shares Unchanged at 250M
The authorized common share count remains at 250,000,000 after the split, creating massive headroom for future dilution — over 220x the current outstanding share count.
-
Nasdaq Compliance at Stake
The reverse split was executed to regain compliance with Nasdaq's $1.00 minimum bid price rule. The stock traded at $1.25 on October 1, 2026, just above the threshold.
-
Cash Crisis Continues
The company had only $747K in cash as of Q2 2026, with a going concern warning and reliance on dilutive financing. The reverse split does not address the underlying cash burn.
Analysis · CDT · Life Sciences
CDT Equity executed a 1-for-25 reverse stock split effective September 28, 2026, reducing outstanding shares to approximately 1.12 million. The split ratio was steeper than the 1-for-10 previously announced in July, reflecting continued pressure on the stock price. The company's authorized share count remains at 250 million, leaving enormous headroom for future dilution. This comes amid a cash crisis — only $747K on hand as of Q2 — and a series of highly dilutive financings, including a $2.1M convertible note to J.J. Astor with VWAP-based conversion. The reverse split is a survival mechanism to maintain Nasdaq listing, but it does not address the underlying cash burn or the overhang from 16.8M shares registered for resale.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1531 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $1.22 to $44,450.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.